Silence Therapeutics plc
SLNHealthcare|Biotechnology|GB
$19.73
+0.01 (+0.05%)
DCF Value
$1.78
Tangible Book / Share
$1.77
Cash / Share
$4.58
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05499013 Study to Assess SLN124 in Patients With Polycythemia Vera | Polycythemia Vera | P1P2 | Active | 69 | RCT, Double-blind | SLN124, Placebo |
| NCT05537571 Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events | Cardiovascular Diseases, Atherosclerosis | P2 | Completed | 180 | RCT, Double-blind | SLN360, Placebo |
| NCT01808638 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) | Carcinoma, Pancreatic Ductal | P1P2 | Completed | 29 | RCT, Open-label | Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2 |
| NCT04718844 A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome | Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome | P1 | Completed | 44 | RCT, Double-blind | SLN124, Placebo |
| NCT04176653 Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124 | Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome | P1 | Withdrawn | — | RCT, Double-blind | SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo |
| NCT04606602 Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) | Hyperlipidemias, Dyslipidemias | P1 | Completed | 70 | RCT, Double-blind | SLN360, Placebo |
| NCT00938574 Study With Atu027 in Patients With Advanced Solid Cancer | Advanced Solid Tumors | P1 | Completed | 34 | Open-label | Atu027 |
| NCT04559971 A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers | Healthy Volunteers | Early P1 | Completed | 24 | RCT, Double-blind | SLN124, Placebo |